What question did this study set out to answer?

The aim is to enhance the repair and regenerative abilities of human cardiac progenitor cells through genetic modification for myocardial infarction treatment.

June 20, 2026Journal of the American College of CardiologyOpen Access

Human Cardiac Progenitor Cells Engineered With Pim-I Kinase Enhance Myocardial Repair

Q: What is the clinical evidence from this study?

Population: Myocardial infarction. Intervention: Human cardiac progenitor cells engineered with Pim-1 kinase (hCPCeP) vs. Human cardiac progenitor cells engineered with GFP (hCPCe). Primary outcome: Myocardial structure and function, cellular engraftment, differentiation, and infarct size.

View Full Paper

Ask AI

Bookmark

Key result

Pim-1-engineered cardiac progenitor cells improve post-infarct cardiac function and reduce injury in mice.

Why the study?

Does intramyocardial injection of Pim-1 engineered human cardiac progenitor cells improve myocardial repair in immunocompromised mice after infarction compared to control cells?

Key Points

The aim is to enhance the repair and regenerative abilities of human cardiac progenitor cells through genetic modification for myocardial infarction treatment.
hCPCs isolated from heart failure patients are genetically modified to express GFP or Pim-1-GFP.
Functional tests conducted with immunocompromised mice via intramyocardial injection post-infarction.
Monitoring of myocardial function through echocardiography and hemodynamic assessments for 20 weeks post-delivery.
hCPCeP show significantly increased proliferation and improved hemodynamic performance at 20 weeks after transplantation.
Enhanced differentiation and engraftment of hCPCeP were observed, with better vasculature and reduced infarct size compared to hCPCe.
Persistence of hCPCeP is maintained up to 8 weeks post-delivery as shown by bioluminescence imaging.

Structured PICO

Does intramyocardial injection of Pim-1 engineered human cardiac progenitor cells improve myocardial repair in immunocompromised mice after infarction compared to control cells?

Population

Immunocompromised mice with myocardial infarction treated with human cardiac progenitor cells engineered with Pim-1 kinase, followed for up to 20 weeks.

Intervention

Intramyocardial adoptive transfer injection of human cardiac progenitor cells engineered to express Pim-1-GFP (hCPCeP)

Comparator

Intramyocardial adoptive transfer injection of human cardiac progenitor cells engineered to express GFP only (hCPCe)

Outcome

Myocardial structure and function assessed by echocardiography and hemodynamics at 20 weeks post-transplantationsurrogate

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Genetic engineering of human cardiac progenitor cells with Pim-1 kinase enhances their survival, engraftment, and reparative efficacy in a preclinical model of myocardial infarction.

Cite This Study

Mohsin et al. (2012) studied Myocardial infarction. Human cardiac progenitor cells engineered with Pim-1 kinase (hCPCeP) vs. Human cardiac progenitor cells engineered with GFP (hCPCe) was evaluated on Myocardial structure and function, cellular engraftment, differentiation, and infarct size. Human cardiac progenitor cells engineered with Pim-1 kinase significantly increased proliferation, ameliorated infarction injury, and improved hemodynamic performance at 20 weeks in mice.

synapsesocial.com/papers/6a3606a7dace31c64cd34966 https://doi.org/10.1016/j.jacc.2012.04.047

View Full Paper

Ask AI

Bookmark

Implication

Genetic engineering of human cardiac progenitor cells with Pim-1 kinase enhances their survival, engraftment, and reparative efficacy in a preclinical model of myocardial infarction.